Page 39 - Pr Team News Today

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint

SHANGHAI, China, March 31, 2023 -- Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of... | March 31, 2023

-- The two parties will collaborate to develop and commercialize toripalimab in 9 Southeast Asian countries through a joint venture company, Excellmab --...

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia

LONDON, ENGLAND / ACCESSWIRE / March 28, 2023 / Proxymity, the leading digital investor communication platform, today announced that State Street, one of the world's leading providers of financial services

Proxymity and State Street Launch Digital Proxy Voting Service in UK ...

Tesla's Twitter presence has notably jumped of late, as the official handle appears to take on PR duties

Issuers, intermediaries, and investors in South Africa to benefit from Proxymity's market-leading and fully connected voting infrastructure. The Citi connection in South Africa, along with the live connection

Really even need it. they were already being a professional pr team for antifa and a lot of different anarchist groups. they really believe in their mission, although they may not say it out loud. >> and the mission, basically, is to not have police in the united states why do you think the fbi hasnt infiltrated antifa. are these guys so good they would sniff out a fed? >> well, you know, i cant really say what the fbi is up to. the only thing i can really tell you is that they really -- if they...

SHANGHAI, China, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated